CDC's HIV Prevention Patents Invalid, Gilead CEO Tells House
Law360 (May 16, 2019, 9:36 PM EDT) -- Gilead believes that Centers for Disease Control and Prevention patents that went toward its blockbuster HIV prevention and treatment medication Truvada are invalid and can't be used to make the company lower the drug's cost, the company’s CEO told the U.S. House of Representatives on Thursday.
That was just one of the many controversial arguments to come out of the House Committee on Oversight and Reform’s three-hour hearing, "HIV Prevention Drug: Billions in Corporate Profits after Millions in Taxpayer Investments."
Lawmakers also sparred over whether the government or Gilead Sciences Inc. was responsible for developing Truvada, when public health needs should...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!